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Introduction
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1. Obesity 
1.1.  Physiological basis of obesity 
Obesity is a global epidemic and contributes to the increasing burden of type 2-diabetes, 
cardiovascular disease, stroke, some types of cancer, and premature death worldwide. 
Our organism is generally more efficient in starvation response since this condition is a 
higher threat to survival; however, in many experimental animals and several humans, 
increase in energy storage promotes long-term and short-term adaptive responses that 
lead to resistance to obesity. These responses, as loss of appetite or increase energy 
expenditure, use the same effector mechanisms that act in response to starvation in 
opposite direction: unfortunately, in current environment, obesity-suppressing stimuli 
are insufficiently robust to prevent obesity and its complications. 
Obesity is caused by perturbations of the balance between food intake and energy 
expenditure, which is regulated by a complex physiological system that requires the 
integration of several peripheral signals and central coordination in the brain. The 
hypothalamus functions as a central regulator in this system. It receives information 
about energy balance through neuronal and hormonal signals to several tissue nuclei 
within it - particularly the ventro-medial, paraventricular and arcuate nuclei - and to the 
lateral hypothalamic area (Xu, B. et al, 2003) (Fig.1). The arcuate nucleus has an 
essential role in this system; it contains two sets of neurons, one produces agouti-related 
protein (AGRP) and neuropeptide Y (NPY) and the other produces pro-
opiomelanocortin (POMC) and cocaine- and amphetamine-related transcript (CART). 
The first type are orexigenic, promoting food intake and reducing energy expenditure, 
and the second type produce the opposite anorexigenic effect (Barsh et al., 2002). 
Peripheral endocrine signals exert their effects through this system over both long- and 
short-term time-frames. Insulin, secreted from beta cells in the pancreas in response to 
elevated blood concentrations of glucose, has a role in the Central Nervous System as a 
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signal of the level of adiposity over a moderate- to long-term period and has an 
anorexigenic effect through stimulation of POMC/CART neurons and inhibition of 
AGRP/NPY neurons (Air, E. L. et al, 2002). The anorexigenic hormone leptin, an 
adipocyte-derived cytokine, seems to be the principal adiposity indicator and signal of 
the state of nutrition, as its plasma levels are highly correlated to adipocyte number and 
fat content (Friedman et al., 1998). However, leptin is involved in the long-term 
regulation of adiposity, and other peptides are responsible for the short-term regulation 
of appetite. One of these, the orexigenic peptide ghrelin, is secreted primarily from the 
stomach and duodenum, and shows a rise in serum levels before eating and a decrease 
after eating (Kohno et al., 2005). Another mediator, peptide YY3–36 (PYY3–36), is 
secreted from the distal gastrointestinal tract on ingestion of food, with concentrations 
peaking within approximately 1 hour. It binds to presynaptic Y2 receptors in the NPY 
neurons that have putative inhibitory effects, which might lead to decreased food intake.  
Satiety is mediated by the response to other factors, such as gut distension and the 
release of the peptide cholecystokinin (CCK) (Spiegelman et al., 2001). 
The central arcuate nucleus processes these different inputs and exerts its effects by 
signalling to various downstream effector neurons. These include the orexigenic 
melanin-concentrating hormone (MCH) neurons and orexin or hypocretin neurons in 
the lateral hypothalamus (Spiegelman et al., 2001), the thyrotrophin-releasing hormone 
(TRH) neurons that are involved in regulating the hypothalamic–pituitary–thyroid axis 
(Flier et al., 2000) and the α- aminobutyric acid (GABA)-releasing interneurons in the 
paraventricular nucleus (PVN), which modulate orexigenic or anorexigenic effector 
neurons.  
Further inputs to this system include the dopamine, serotonin and endocannabinoid 
signalling systems (Fig. 1).  
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Figure 1 | Physiological regulation of energy balance.  
The neuropeptide Y (NPY)/agouti-related protein (AGRP) neurons, and the pro-opiomelanocortin 
(POMC)/cocaine and amphetamine related transcript (CART) neurons in the arcuate nucleus of the 
hypothalamus have key roles in the regulation of energy balance. Activation of the NPY/AGRP neurons 
has an orexigenic effect, promoting food intake, whereas the POMC/CART neurons have the opposite 
anorexigenic effect.  
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This weight-regulatory system is a powerful protection against weight loss; however, 
the same cannot be said for weight gain (Schwartz et al., 2003). 
Signals from fat to brain regulate many processes including appetite and energy 
expenditure. With increasing adiposity, the consequent rise in leptin has a limited effect 
on reducing food intake and averting obesity (Considine et al., 1996). 
The anti-obesity role of leptin is limited by cellular resistance to this signal, which 
might have developed in response to evolutionary pressure to promote fat storage and so 
protect against starvation (Spiegelman et al., 2001). 
Analysis of physiological pathways has highlighted possible candidate genes that might 
underlie the genetic basis of obesity. In general, genetic studies have contributed 
significantly to understanding the physiology of weight regulation, through both the use 
of animal models and the investigation of the genetics of rare and common human 
forms of obesity. 
 
1.2.  Genetic of human obesity 
Obesity is an important cause of morbidity and mortality in developed countries, and is 
also becoming increasingly prevalent in the developing world. Although environmental 
factors are important, there is considerable evidence that genetic predisposition also has 
a significant role in its pathogenesis. The identification of genes that are involved in 
monogenic, syndromic and polygenic forms of obesity has greatly increased our 
knowledge of the mechanisms that underlie this condition (Bell et al., 2005).  
It is well established that mutations in genes that encode proteins with likely roles in 
appetite regulation are responsible for Mendelian disorders in which obesity is the most 
obvious phenotype.  
Monogenic forms of obesity are represented from mutations in the gene that encode 
leptin (Zhang et al., 1994), the leptin receptor (LEPR) (Tartaglia et al., 1995), 
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carboxypeptidaseE (responsible for processing prohormone intermediates, such as 
proinsulin) (Naggert et al., 1995), Pro-opiomelanocortin (POMC) and melanocortin-4 
receptor (MC4R) (Huszar et al., 1997).  
A key role of leptin in some monogenic forms of obesity was further supported by the 
striking effect of leptin replacement in an extremely obese child with congenital leptin 
deficiency. In this 9-year-old child, the daily subcutaneous injection of recombinant 
human leptin for a year led to a complete reversal of obesity, with sustained fat-mass 
loss (Farooqi et al., 1999). However, only a handful of families with extreme forms of 
obesity in early infancy have mutations in these genes. 
However, individuals with monogenic forms of obesity represent only a small fraction 
of the obese population and many other candidate genes have been evaluate as 
contributor to polygenic forms of obesity (Loos and Bouchard, 2003). Many studies 
have demonstrated that polymorphisms located in genes and candidate genetic loci 
concur to determine an individual’s susceptibility to weight gain (Clement, 2006). 
With the increasing scale of the obesity problem and the body of evidence outlined 
above for a strong genetic contribution to development of the disease, many groups 
have started to study the genetics of polygenic obesity to better understand the 
pathogenesis of the disease and highlight possible pharmacological targets. Two 
approaches that are commonly used across the whole field of complex human genetics 
have been used to identify the underlying genes: candidate-gene and whole-genome 
approaches. However, many other genetic alterations contribute to development of 
obesity phenotype.  
At least 20 rare syndromes that are caused by discrete genetic defects or chromosomal 
abnormalities, both autosomal and X-linked, are characterized by obesity. 
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Most of these obesity syndromes are distinguished by the presence of mental 
retardation, severe hyperphagia, and/or other signs of hypothalamic dysfunction, 
indicating an origin at the level of the CNS (Delrue et al., 2004). 
The most frequent of these syndromes (1 in 25,000 births) is Prader–Willi syndrome 
(PWS), an autosomal-dominant disorder that is characterized by obesity, hyperphagia, 
diminished foetal activity, muscular hypotonia, mental retardation, short stature and 
hypogonadotropic hypogonadism caused by deletion at the chromosomal region 
15q11.2–q12 (Jiang et al., 1998), sometimes associated with the deletion or disruption 
of the single minded homologue 1 (SIM1) gene, in humans (Holder et al., 2000). 
Pseudohypoparathyroidism type 1A (PHP1A) syndrome is due to a maternally 
transmitted mutation in GNAS1, which encodes the α-subunit of the GS PROTEIN.  
Food-intake abnormalities in patients with this syndrome might be due to the expression 
of the resulting variant Gs protein in the hypothalamic circuitry that controls energy 
balance, which involves many G-protein coupled receptors (Spiegel et al., 2004). 
The candidates discussed here and listed in Table 1 are only a small selection of those 
published, and a more complete list can be found at the Obesity Gene Map database 
(Obesity Gene Map database: http://obesitygene.pbrc.edu). As would be expected, 
owing to both experimental and statistical variation, there have been studies that have 
reported no association for all of these genes; however, from the available functional 
data, they are all plausible candidates for genes that are involved in common obesity.  
These genes are involved in the regulation of energy metabolism, appetite control or 
autocrine–paracrine signalling by adipocytes. 
It is clear from the descriptions above that the molecular causes that underlie the 
aetiology of syndromic obesity are more complex than for monogenic cases, and further 
studies are required to elucidate their genetic basis.  
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Table 1: A selective list of genes that are associated with obesity phenotypes 
The list includes genes for which markers have been shown to be associated with obesity-related 
phenotypes in multiple published studies. A more complete list can be found at the Obesity Gene Map 
Database (see Online links box). 
*Official gene symbols and names are from the HUGO nomenclature committee web site 
(http://www.gene.ucl.ac.uk/nomenclature). ‡Chromosomal band location is as listed in the NCBI 
database. ||Short-hand descriptions of associated phenotypes that are statistically significant at p <0.05. 
BMI, body mass index; WHR, weight–hip ratio. 
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2. Gene expression in adipose tissue 
Obesity is highly heritable and arises from the interactions of multiple genes, 
environmental factors, and behaviour. Epidemiologic, and then molecular, studies 
confirmed this pathogenesis: from 30 to 80% of weight variation are related to genetic 
factors and moreover, that more than 50% of all gene expression traits in adipose tissue 
are strongly correlated with clinical traits related to obesity (Emilsson et al., 2008). 
A different gene expression emerged in adipose tissues of obese subjects respect to 
those of lean individuals also in dependence of sex, diet, exercise and hormonal factors. 
By microarray technology a change of expression at trascriptome level in adipose tissue 
has been previously evaluated (Gomez-Ambrosi et al., 2003; Viguerie et al., 2005). A 
general down-regulation of lipolysis-inducing genes and up-regulation of mitogen-
activated protein kinases (MAPK) have been observed together with a general increase 
of the expression of inflammatory citokines and immune system-related genes (Gomez-
Ambrosi et al, 2003). The metabolic and endocrine functions of adipose tissue from 
various depots differ in a way that may explain the association of visceral but not 
subcutaneous fat with obesity-related cardiovascular and metabolic problems (Arner, 
1998). 
Regarding the metabolic function of fat, visceral adipose tissue is more sensitive to the 
stimulation of lipolysis by cathecolamines, whereas subcutaneous fat is more sensitive 
to the antilipolytic effects of insulin. Concerning endocrine function, visceral and 
subcutaneous adipocytes have different capacities to produce hormones and enzymes. 
Depot-related variation in mRNA expression has been shown for several genes, 
including leptin, TNF- , angiotensinogen, PAI-1 (Arner, 1998), and recently, 
carboxypeptidase E and thrombospondin-1 (Ramis et al., 2002). The mechanisms 
responsible for depot differences in adipose function are unknown. It is possible that fat 
cells in various regions have different origins and, because of this, express different 
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genes (Fig. 2). Recent indirect evidence supports this idea, because newly formed 
adipocytes in human subcutaneous and visceral fat were shown to maintain the 
phenotypic site differences of mature adipocytes (Van Harmelen et al., 2002). 
 
3. MicroRNA 
3.1.  Biogenesis 
Gene regulatory factors that control the expression of genomic information come in a 
variety of flavors like microRNAs representing the most numerous gene regulatory 
factors in multicellular genomes (Hobert et al., 2008). 
These molecules are non-protein-coding small RNAs (microRNAs) are approximately 
21–23 nucleotides in length, and act by negatively regulating gene expression at the 
post-transcriptional level (Lagos-Quintana et al. 2001, Lau et al. 2001, Bartel 2004).  
Mature miRNAs are derived from two major processing events, driven by sequential 
cleavages by the RNAse-III enzymes Drosha and Dicer (He & Hannon 2004 and Kim 
2005). Briefly, miRNAs are transcribed by RNA polymerase II, producing primary-
miRNAs (pri-miRNAs) (Lee et al. 2002, 2004).  
Pri-miRNAs, often several kilobases long, are polyadenylated and capped, similar to the 
production of mRNAs from protein encoding genes (Cai et al. 2004, Lee et al. 2004). 
These pri-miRNAs are then subjected to processing by the microprocessor complex, 
composed of Drosha and its associated binding partner, Pasha (also known as DGCR8 
in mammals), which results in the excision of a 65–75 nucleotide stem-loop precursor 
called a pre-miRNA (Lee et al. 2003, Landthaler et al. 2004). 
These pre-miRNAs are then recognized and transported from the nucleus to the 
cytoplasm via the Ran-GTP dependent nuclear transmembrane protein, Exportin5, 
where they are than subjected to a second cleavage step by Dicer (Yi et al. 2003, Lund 
et al. 2004). 
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Figure 2 | Schematic overview indicating genes that may be implicated in the mediation of the 
pathological consequences of obesity or involved in the genetic susceptibility to obesity. 
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Processing by Dicer results in the production of a small double-stranded miRNA duplex 
containing 2-nucleotide-long 3' overhangs (Bernstein et al. 2001). These double-
stranded products are thought to be quickly unwound by an as yet unidentified helicase, 
and a single mature strand can be asymmetrically incorporated into the RNA-induced 
silencing complex (RISC) (Khvorova et al. 2003, Schwarz et al. 2003) where they can 
then act by translational repression (by a cleavage-incompetent RISC) or mRNA 
degradation (by a cleavage-competent, Slicer-containing RISC) (Tang, 2005). 
MicroRNA can have two mechanisms for post-transciptional gene silencing and they 
act by mediating translational repression or degradation of the mRNA targets. In 
animals, most miRNAs are thought to function by translational repression, whereas in 
plants mRNA degradation is thought to be the primary mechanism by which they 
exhibit their silencing effects. Translational repression is thought to occur when the 
miRNA imperfectly pairs to the target mRNA, although the precise mechanism has yet 
to be elucidated (Fig. 3).  
The degree of repression is often correlated with the number of miRNA binding sites, 
most of which are thought to occur in the 3' untranslated regions (UTRs) of the targets, 
but which can potentially bind to complementary sequences in the open reading frame 
(ORF) or 5' UTR (Doench & Sharp 2004). In contrast, mRNA degredation is thought to 
occur by siRNA-acting miRNAs. siRNA-acting miRNAs form perfect/near perfect 
interactions with their target mRNAs, which results in the cleavage of the mRNA 
known as RNA interference (Fig. 3) (Rhoades et al. 2002). This perfect/near perfect 
association presumably triggers the action of Slicer, which in mammals is putatively 
thought to be the Argonaute2 (Ago2) endonuclease acting either alone or in addition to 
other Argonaute or as yet unknown proteins within the RISC complex (Liu et al. 2004b, 
Meister et al. 2004, Okamura et al. 2004).  
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Figure 3 | MicroRNA biogenesis pathway.  
MicroRNA (miRNA) genes are generally transcribed by RNA Polymerase II (Pol II) in the nucleus to 
form large pri-miRNA transcripts, which are capped (7MGpppG) and polyadenylated (AAAAA). These 
pri-miRNA transcripts are processed by the RNase III enzyme Drosha and its co-factor, Pasha, to release 
the 70-nucleotide pre-miRNA precursor product. (Note that the human let-7a-1 miRNA is shown here 
as an example of a pre-miRNA hairpin sequence. The mature miRNA sequence is shown in red.)  
RAN–GTP and exportin 5 transport the pre-miRNA into the cytoplasm. Subsequently, another RNase III 
enzyme, Dicer, processes the pre-miRNA to generate a transient 22-nucleotide miRNA:miRNA* 
duplex. This duplex is then loaded into the miRNA-associated multiprotein RNA-induced silencing 
complex (miRISC) (light blue), which includes the Argonaute proteins, and the mature single-stranded 
miRNA (red) is preferentially retained in this complex. The mature miRNA then binds to complementary 
sites in the mRNA target to negatively regulate gene expression in one of two ways that depend on the 
degree of complementarity between the miRNA and its target. miRNAs that bind to mRNA targets with 
imperfect complementarity block target gene expression at the level of protein translation (lower left). 
However, recent evidence indicates that miRNAs might also affect mRNA stability (not shown). 
Complementary sites for miRNAs using this mechanism are generally found in the 3' untranslated regions 
(3' UTRs) of the target mRNA genes. miRNAs that bind to their mRNA targets with perfect (or nearly 
perfect) complementarity induce target-mRNA cleavage (lower right). miRNAs using this mechanism 
bind to miRNA complementary sites that are generally found in the coding sequence or open reading 
frame (ORF) of the mRNA target. 
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Slicer functions by cleaving the target mRNA between the 10th and the 11th nucleotide 
from the 5' end of the miRNA (Tuschl et al. 1999, Liu et al. 2004a). Thus far, only a 
handful of mammalian miRNAs have been shown to act in a siRNA-like manner. One 
example is miR-196, which directs the cleavage of the HOXB8 transcript (Mansfield et 
al. 2004, Yekta et al. 2004), and it will be interesting to determine if there are others that 
can act by this mechanism. Intriguingly, knockout of Ago2 in mice is lethal as it is 
required for development, suggesting that a cleavage-competent RISC is essential in 
mammals (Liu et al. 2004b). This finding, along with the evolutionary conservation of a 
cleavage-competent RISC suggests that there may be more siRNA-acting microRNAs.  
 
3.2.Function 
MicroRNAs have been originally describe in Caenorhabditis elegans (miRNA family, 
lin-4) and they have been viewed this RNA as an oddity in worm genetics (Lee et al. 
1993). Seven years passed before the discovery of another C. elegans miRNA, let-7, 
which also was found to regulate developmental timing in these animals (Reinhart et al. 
2000). This time, however, the discovery was particularly intriguing because let-7 is 
highly conserved among bilaterally symmetrical animals (Pasquinelli et al. 2000).  
Accumulating studies have confirmed that about 1,000 of these RNAs are encoded in 
animal genomes, and the most recent computational studies estimate that up 30% of 
human genes may be regulated by microRNA 12-13 and also distinct miRNAs in 
humans, together potentially regulating a large portion of protein-encoding genes (and 
possibly non-protein-encoding genes as well) (Berezikov et al. 2005). Now, it knows 
that miRNAs play an important role in translation regulation in plants, Drosophila and 
mammals (Table 2). 
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Table 2: Summary of miRNAs Involved in Mammalian Development 
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In mammals, they have been shown to regulate stem cell fate, developmental and tissue 
specificity, demonstrating that their expression can be regulated both temporally and 
spatially, adipocyte differentiation, insulin secretion, B-cell development and they may  
be important for proper immune function (Esau et al. 2004, Smirnova et al. 2005) and 
the disregulation of these small RNAs may participate in the pathogenesis of prevalent 
human diseases, including diabetes, cancer DiGeorge Sindrome, and various virus-
related and virus-induced deseases (Zhang et al., 2007, Fabbri et al., 2008). MicroRNAs 
have been shown to regulate the fat metabolism pathway. MiR-14 was the first 
microRNA reported to be involved in fat metabolism. Inhibiting miR-14 expression 
results in increased levels of triacylglycerol and diacylglycerol in the fruit fly, 
Drosophila (Xu et al. 2003). MiR-122, a liver-specific microRNA, is a key regulator of 
cholesterol and fatty acid metabolism, and is responsible for the up-regulation and 
down-regulation of several hundred genes (Krutzfeldt et al., 2005, Esau et al., 2006).  
By using antagomirs, short RNA molecules designed to silence microRNAs, to inhibit 
miR-122 in a diet-induced obese mouse, a decrease in plasma cholesterol levels and 
considerable improvement in hepatic steatosis were observed.  
There is also evidence that miR-278 is involved in energy homeostasis in Drosophila 
(Teleman et al., 2006). Mutants lacking miR-278 are lean. The reason may be that miR-
278 mutants have elevated insulin production and sugar circulation mobilized from 
adipose-tissue glycogen stores. A considerable body of research suggests the potential 
role of microRNAs as attractive pharmacological agents for metabolic diseases such as 
obesity. Others were discovered to be important regulator of endocrine functions. The 
discovery of a pancreatic islet-specific miRNA, miR-375, that inhibits insulin secretion 
in mouse pancreatic ß-cells, uncovered a novel component of the insulin secretion 
machinery (Fig. 4A) (Poy et al. 2004). miR-375 is believed to act by inhibiting the 
expression of myotrophin (also known as V-1), a cytoplasmic protein that induces the 
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exocytosis of insulin granules (Poy et al. 2004). Since type 2 diabetes results from 
combined defects in insulin secretion and insulin action, miRNAs may have a role in the 
pathogenesis of this disorder. 
Another miRNA that may play a role in endocrine function is miR-143, which has been 
proposed to play a role in adipocyte differentiation (Fig. 4B) (Esau et al. 2004). 
Investigators found that reducing the level of this miRNA by transfecting 2'-O-
methoxyethyl phosphorothioate-modified antisense RNA oligonucleotides into human 
pre-adipocytes in vitro inhibited their differentiation, as determined by the decreased 
expression of 4 adipocyte-specific genes (GLUT4, HSL, fatty acid-binding protein aP2 
and PPAR- 2) and their inability to accumulate triglycerides. Computationally, miR-
143 has been predicted to have several targets (Lewis et al. 2003), and the authors 
determined that knockdown of miR-143 led to upregulation of one of the predicted 
targets, ERK5/BMK1. ERK5 is thought to promote cell growth and proliferation, which 
is consistent with the phenotype observed (inhibition of differentiation), but it still 
remains to be determined whether other targets of miR-143 also contribute to the 
phenotype.  
Since excess adiposity is rampant in western countries, and contributes to several 
common diseases including type 2 diabetes, hypertension and coronary heart disease, 
new insights provided by the study of miRNAs in adipocyte biology and long-term 
energy storage could have a tremendous clinical impact.  
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Figure 4 |  Roles of miR-375 and miR-143. 
(A) miR-375 has been shown to be expressed in pancreatic β-cells and is thought to play a role in insulin 
secretion. In addition, 67 other β-cell-specific miRNAs have been discovered, although their functions 
have yet to be elucidated. (B) miR-143 has been proposed to have a role in adipocyte differentiation, and 
inhibition of this miRNA leads to down-regulation of proteins that have a known role in this process 
(GLUT4, HSL, aP2, and PPAR-γ2 (PPAR-g2)). It is unclear if there are additional miRNAs that are 
critical for adipocyte differentiation and maturation. 
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4. Aims of the project 
MicroRNA are believed to be generally involved in more quantitative regulation of 
mammalian trait: therefore, mammalian conditions that have a strong genetic 
component and involve quantitative differences between the physiological and 
pathological conditions are strong candidates to be influenced by miRNA 
disregulations. The pool of this study is thus to investigate the possible role for miRNA 
imbalance in adipose tissue in the development of obesity.   
To date, microRNAs have been identified and evaluated in human preadipocytes  (miR-
143) and mouse hepatocytes (miR-122). There is no study dealing with microRNA in 
subcutaneous adipose tissue (SAT) of obese patients. 
For this reason, we have performed an high-throughput screening by microarray 
analysis on 1,458 microRNAs in SAT from 20 morbidly obese patients (10 men and 10 
female) versus pools of RNA from non obese subjects (3 men and 5 female). 
We were able to identify miRNAs differentially expressed comparing SAT from obese 
patients with respect to SAT from non-obese patients. 
The miR-519d was significantly higher in obese subjects than in the non obese pools. 
Using bioinformatic and functional analyses, we have demonstrated that the peroxisome 
proliferator activated receptor A (PPARA) gene resulted be a target of miR-519d. 
PPARA regulates the genes involved in fatty acid, glucose metabolism and 
inflammation (Cho et al., 2008). Therefore, it is conceivable that loss of PPARA could 
cause metabolic imbalance, thereby resulting in adipocyte hypertrophy in SAT from 
morbidly obese subjects. 
This project set the goal to be a part of the effort in understanding the biology and the 
role of this miR-519d during biogenesis of obesity. 
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Materials and Methods
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1. Subjects 
Subjects were divided into two groups based on body mass index (BMI) used as index 
of overall adiposity: morbidly obese subjects (BMI>40 kg/m2) and non obese subjects 
(BMI<30 kg/m2). 
The obese subjects included (10 men and 10 women) a subgroup of patients 
participating in a clinical trial of adjustable gastric banding (Thorne et al., 2002).  
The non obese subjects (3 men and 5 women) underwent abdominal surgery because of 
benign diseases (i.e. laparoscopic cholecystectomy). From these subjects, it was 
possible to obtain fat specimens from omental as well as subcutaneous adipose tissue 
(the latter was taken from the surgical incision).  
All subjects were Caucasian (Table 3).  
 
 
Table 3: Clinical characteristics subjects 
 
Measure Obese 
(value±SD) 
Non-Obese 
(value±SD) 
n 
 
20 
 
7 
 
Age, years 
 
41.1± 3.3 42.2±7.5 
 
Body mass index,  (kg/m2) 
 
42.7 ± 1.2 24.7±1.6 
 
PL-glucose, mmol/l 
 
5.2 ± 0.2 4.5 ± 0.2 
 
PL-cholesterol, mmol/l 
 
5.1 ± 0.3 5.0 ± 0.3 
 
PL-triglycerides, mmol/l 
 
1.4± 0.1 1.1 ± 0.2 
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Eating habits (gorging behavior [70%] and sweet-eaters [30%]), familial history of 
obesity (30%) and clinical history were recorded for all obese patients. Hypertension 
was present in 45% of obese patients. Neoplasia, diabetes and alcohol abuse were 
excluded in all but two subjects: one obese subject was affected by type 2 diabetes and 
another was addicted to alcohol. All subjects provided written informed consent to the 
study and the research protocol was approved by the Ethics Committee of our Faculty 
of Medicine. 
 
2. Samples 
Subcutaneous adipose tissues (SAT) were obtained from individual subjects.  
SAT aliquots (about 100-600 mg), not in contact with abdominal district, were collected 
during surgery. Elettrocauterization was limited to reduce the rate of necrosis. All 
biopsies were snap-frozen and stored in liquid nitrogen until total RNA isolation and 
protein purifications. A blood sample was obtained by venipuncture from all fasted 
subjects the day before the surgery for adipokine analysis and other biochemical 
measurements. 
 
3. Measurement of adipokines and other biochemical markers 
The Bio-Plex suspension array system (Bio-Rad, Hercules, CA), which employs a 
fluorescent bead based immunoassay, was used to measure adipokine markers of 
obesity and cytokines: adiponectin, adipsin, ghrelin, leptin, resistin, Il-6 and TNF-α, in 
serum samples of obese and non obese subjects, according to the manufacturer’s 
protocol. Briefly, a nine-point standard curve was generated by performing serial 
dilutions of the reconstituted normalized standard; the assays were run in duplicate. 
Bioplex manager software was used to analyze data obtained. Main biochemical 
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parameters (total cholesterol, triacylglycerides, glucose, etc.) were measured by 
standard methods. 
 
4. RNA extraction 
Total RNA was extracted from frozen subcutaneous adipose tissue (SAT) samples by 
homogenization in guanidine thiocyanate-phenol solution (QIAzolTM Lysis Reagent; 
Qiagen) and then purified using mirVana miRNA Isolation Kit (Ambion, Austin, TX, 
USA), according to the manufacturer's protocol. RNA concentrations and purity were 
evaluated with the NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). RNA integrity was verified using the Agilent 2100 
Bioanalyzer (Agilent Technologies). 
 
5. MicroRNA expression profile 
The expression profiles of microRNAs in SAT were determined using the miRCURY™ 
LNA miRNA Array V8.1 (208002V8.1-Lot n. 20393.03, Exiqon, Denmark), which 
contains complementary probes for the mature forms of all microRNAs registered in 
miRBase 8.1 (Griffiths-Jones et al., 2006). The microarray consist of 1458 capture 
probes, perfectly matched to human microRNAs annotated in miRBase 8.2, control 
probes and mismatch probes. The reference RNA consisted of a pool of total RNA 
isolated from three non obese control males (CM) and five non obese control women 
(CW) used for the hybridization of obese males and obese women, respectively. Total 
RNAs of controls were labeled with Cy3 and total RNAs of obese subjects with Cy5 
using the miRCURY™ LNA miRNA Array labeling kit following the instruction 
manual. For each sample, 1 µg of total RNA was labeled hybridized and washed 
manually using the Agilent microarray hybridization chambers SureHyb. 
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Microarrays were scanned on an Agilent DNA Microarray Scanner (Agilent 
Technologies) and raw data were extracted using the Feature Extraction software 
(Agilent Technologies). Data were subsequently analyzed using GeneSpring® version 
7.2 (Agilent Technologies), and statistical analysis was performed using background-
corrected mean signal intensities from each dye channel. 
Microarray data were normalized using intensity-dependent global normalization 
(LOWESS). 
Differentially expressed microRNAs were identified using a filtering by standard 
deviation (0-2) and the Benjamini and Hochberg False Discovery Rate (p-value 0.05) to 
minimize selection of false positives. Of the significantly differentially expressed 
microRNA, only those with a greater than log2 1.5-fold increase or decrease in 
expression of obese subject compared with non obese controls were used for further 
analysis.  We also used hierarchal gene-tree clustering analysis, and default parameters, 
to group microRNAs with similar expression profiles. 
 
6. Real-time polymerase chain reaction quantification of 
selected mRNA 
Real-time quantitative PCR was carried out on the Applied Biosystems 7900HT 
Sequence Detection system (Applied Biosystems, Foster City, CA). cDNAs were 
synthesized from the same total RNAs utilized in the microarray experiments using 
hexamer random primers and multiscribe reverse transcriptase (Applied Biosystems). 
Approximately 1/20th of the resultant cDNA was used for PCR analysis.  
We used the oligonucleotides primers for following selected genes:  
- SLC2A4 (solute carrier family 2 (facilitated glucose transporter), member 4):   
  FW: GCCCCCGCTACCTCTACATC, RW: GCCTGTCAGGCGCTTCA;   
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- PPARA (peroxisome proliferator-activated receptor alpha): 
  FW: TTGCTGTGGAGATCGTCCTG, RW: CATGTACAATACCCTCCTGCATTT;  
- 18S:  
  FW: CGGCTACCACATCCAAGGAA, RW: GCTGGAATTACCGCGGCT .  
The PCR conditions for reverse transcription (RT) were: stage 1: 50°C, 2 min; stage 2: 
95°C, 10 min; and stage 3: 95°C, 15s ; 60°C, 1 min/40 cycles.  
In parallel, RT-PCR was performed by using the TaqMan miRNA Assay Protocol to 
assess the relative expression of a subset of microRNAs. The fold changes of mir-519d 
was normalized to U6 RNA. For RT reactions, 10 ng total RNA was used in each 
reaction and mixed with the corresponding TaqMan miRNA assays RT primer. The RT 
reaction conditions were: 16°C for 30 min; 42°C for 30 min; 85°C for 30 min and then 
hold on 4°C. After the RT reaction, 1.33 µl of cDNA was used for the PCR reaction 
together with TaqMan primers. The PCR reaction was carried out at 95°C for 10 min, 
followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. 
 
7. Protein extraction and western analysis 
Total proteins were extracted from frozen adipose tissue. 200 mg of each sample were 
homogenized with 1 ml of lysis buffer (2% SDS, 10% glycerol, 5% β-mercaptoethanol, 
6.25 mmol/L Tris-HCl pH 6.8 and a cocktail of protease inhibitors (aprotinin 2 mg/ml, 
leupeptin 2 mg/ml, phenylmethanesulfonyl fluoride 100 mg/ml, pepstatin A 1 mg/ml). 
Protein concentrations were quantified using the Bradford assay (BioRad Laboratories). 
For each sample, 50 mg of total proteins were separated by SDS-PAGE (15% for 
PPARA and SLC2A4) and electroblotted onto polyvinylidene difluoride (PVDF) 
membranes (Amersham) for 19 h at 33 V. Blots were blocked with 5% bovine serum 
albumin (BSA) in tris-buffered saline tween-20 [(TBST): 25 mM Tris, pH 7.4, 3.0 mM 
KCl, 140 mM NaCl and 0.1% Tween 20] for 1 h at room temperature. The blots were 
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incubated with the specific monoclonal antibody; alpha-actinin (dilution 1:1000), 
PPARA (dilution 1:400); SLC2A4 (dilution 1:200) in the same solution for 1 h. The 
membranes were rinsed in TBST and incubated for 45 min in TBST buffer with anti-
goat IgG, HRP-labeled secondary antibody (dilution 1:5000) for PPARA, SLC2A4 and 
alpha-actinin.  
All antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Immunoreaction signals were visualized with enhanced chemiluminescence (ECL-
PLUS, Amersham Biosciences). 
 
8. Oligonucleotides and plasmids 
Chemically modified double-stranded RNA molecules designed to up-regulate (pre-
miR-519d microRNA precursor molecules) and down-regulate (anti-miR-519d 
microRNA inhibitors) endogenous microRNAs were purchased by Ambion (Austin, 
TX, USA). The plasmids used were pGL3-control encoding for firefly luciferase and 
pRL-PPARA coding for Renilla luciferase (Promega) modified by insertion of the part 
of the 3’ UTR region of the PPARA gene containing miR-519d binding sites (1586-
2035 bp in the cDNA) in the XbaI site of the pRL-CMV (Promega). The direction of the 
inserted 3’ UTR region was confirmed by PCR and sequencing after ligation. 
 
9. Cell cultures 
The cell lines used were human HEK-293 maintained in α-MEM (minimum essential 
medium) supplemented with 10% fetal bovine serum and glutamine. 
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10. Transfection and inhibition experiments 
HEK-293 cells were seeded in 24-well plates with 500 µl of antibiotic-free medium the 
day before transfection to allow adherence and reach 70–90% confluence at the time of 
transfection. The standard co-transfection mix was prepared for triplicate samples by 
adding 75 ng pGL3-control, 30 ng pRL-PPARA and pre-miR and anti-miR as indicated 
in the various experiments in 150 µl of Opti-MEM I (Invitrogen); 3 µl lipofectamine 
2000 (Invitrogen) was added separately in 150 µl Opti-MEM I. The two solutions were 
mixed and incubated at room temperature for 20-30 min, after which, 100 µl of the mix 
was added to each well. The final volume of medium plus transfection mix was 600 µl. 
Cells were incubated with the transfection mix for 4 h and the medium was then 
replaced with new fully supplemented culturing medium. Twenty-four hours after 
transfection, firefly and Renilla luciferase activities were measured using a dual 
luciferase assay according to the manufacturer’s instructions (Promega). 
 
 
30 
Results
 
 
31 
1. Identification of miRNAs on subcutaneous adipose tissue 
through microarray analysis 
The recent development of high-throughput gene expression technology permits 
simultaneous investigation of thousands of genes, providing a snapshot of the 
transcription state of diseased tissue. Microarray based expression profiling is well 
suited to investigate the molecular basis of complex diseases such as obesity 
(Baranova et al., 2005). 
In the present study, a microarray screening was carried out on subcutaneous adipose 
tissue (SAT) in order to identify miRNAs differentially expressed that might be relevant 
in the development of obesity.  
In order to analyze the miRNA expression profiles we used microRNA microarrays that 
contain high affinity LNA-based capture probes for all human microRNAs in the 
release 8.2 of the miRBase microRNA Registry (http://microrna.sanger.ac.uk/).  
LNA (Locked Nucleic Acid)-modified oligonucleotides have been used as sensitive and 
specific miRNA detection probes (Castoldi et al., 2006). Incorporation of LNA into the 
probes increases the affinity for the complementary miRNA targets. This LNA-array 
captures probes are therefore more sensitive than DNA probes and are designated with a 
uniform Tm that guarantees that each miRNA hybridizes to the array with equal affinity 
and specificity. LNA array consists of control probes snRNAs (U6), that are commonly 
user for normalization, mismatch probes, a non-target capture probe and target capture 
probe. Several of the capture probes included are designed for synthetic target that do 
not occur biologically. 
We used 1458 different capture probes to evaluate the different expression of 
microRNAs in adipose tissue from two groups of subjects. The first group is composed 
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of 10 obese woman (OBW) and 10 obese men (OBM); all subjects were extremely 
obese with a BMI≥40 and undergoing surgery to reduce body weight.  
The second group  is composed of 3 non-obese man (CM) and 5 non-obese woman 
(CW) controls with a BMI ≤ 30 and normal adipose tissue distribution that underwent 
surgery for others conditions. 
We extracted, from samples of subcutaneous adipose tissues from each subject, RNA 
and proteins. 
We chosed RNA from subcutaneous because its uniform tissue composition and 
absence of immune system cells that are, on the other hand, abundant in omental fat 
(Linder et al., 2004).  
Total RNA has been purified and quantified and only high quality RNA was used for 
the screening. Subcutaneous adipose tissue RNA of obese patients was labelled with 
fluorochrome Cy3 while adipose tissue RNA of non-obese patients was pooled and 
labelled with fluorochrome Cy5 served as controls. 
Expression profiling revealed that a large set of microRNAs was expressed in SAT. 
Forty-two microRNAs differed by at least log2±1.5 fold (p-value<0,05) in 17/20 obese 
subjects versus the non obese control pools. Of the forty-two microRNAs differed, 21 
were up-regulated and 21 were down-regulated. Among the differentially expressed 
microRNAs, in 20/20 obese subjects, three microRNA were up-regulated (Fig. 5), 
whereas two microRNA were down-regulated (Fig. 6). 
Our attention was focused on the up-regulated miR-519d, the microRNA significantly 
higher in obese subjects than in the non obese pools.  
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Figure 5 | Up-regulated microRNAs in 20/20 severely obese subjects.  
MicroRNA expression profiles obtained from LNA microRNA Arrays V 8.1 of subcutaneous adipose 
tissue from obese men and women. 
The rows represent different microRNA probes on the microarray, and the columns represent individual 
RNA samples. The scale at the top indicates relative microRNA expression changes in log2 units, where 
0 represents the mean expression level of a given microRNA across samples. 
 
 
 
 
 
 
 
 
hsa – mir – up r. 
hsa – mir – up r. 
hsa – mir – 519d 
 
 
 34 
 
 
 
 
Figure 6 | Down-regulated microRNAs in 20/20 severely obese subjects.  
 
hsa – mir – down r. 
hsa – mir – down r. 
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2. Real -Time PCR 
In order to confirm the results of microarray analysis, microRNAs expression from the 
same samples from obese and non-obese groups were analyzed by Real-Time PCR 
assay. 
Real-Time PCR assay is a highly sensitive approach for identifying miRNA profiles 
(Chen et al., 2005). For this assay, we have used stem–loop RT primers rather than 
conventional linear ones, because of their higher specificity and sensitivity likely due to 
the base stacking and spatial constraint of the stem–loop structure. The assays target 
only mature microRNAs, not their precursors, ensuring biologically relevant results. 
In almost all patients, microarray profiling data correlated with real-time RT-PCR data 
(Fig. 7).  In fact, the expression levels of miR-519d were confirmed in OBW and in 
OBM versus CW and CM, respectively.  
 
3. Identification of miRNA target 
Computational algorithms have been the major driving force in predicting miRNA 
targets (Rajewsky, 2006). These approaches are mainly focused on programming 
alignment to identify complementary elements in the 3’-UTR with the seed sequence of 
the miRNA and the phylogenetic conservation of the complementary sequences in the 
3’-UTRs of orthologous genes. However, evidences suggest that perfect seed pairing 
may not necessarily be a reliable predictor for miRNA interactions (Diadian and Hobert, 
2006), which may explain why some predicted target sites are non functional. Hence, 
with few exceptions, most physiological, and clinically relevant, targets for miRNAs 
remain to be identified or verified experimentally. Currently there is no clear consensus 
as to what criteria should be followed to determine miRNA targets and to confirm their  
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Figure 7 | microRNA expression levels in subcutaneous adipose tissue from morbidly obese 
subjects.  
MiR-519d expression levels are very high in morbidly obese women and men, respectively. 
A: obese women [OBW], CW, control women pool; B: obese men [OBM, CM, control men pool.  
Data are expressed as RNA fold change in obese patients versus non obese control pool (RQ=2^[-delta 
deltaCt]). 
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biological efficacy. A set of guidelines has been  establish how investigators can 
validate the hypothesis that a given miRNA regulates a specific mRNA target as 
showed in the following scheme (Fig. 8). 
A predetermined gene as a target of miRNA regulation, individual gene sequences (i.e. 
3’-UTR mRNA sequences) may be analyzed by various computational algorithms 
which utilize distinct parameters to predict the probability of a functional miRNA 
binding site within a given mRNA target.  
There are three bioinformatic algorithms, used in different applications, that are capable 
to predict miRNA target sites: miRanda (http://microrna.sanger.ac.uk) (Griffiths-Jones 
et al., 2006); TargetScan (http:// www.targetscan.org) (Grimson et al., 2007); and, 
PicTar (http://pic.tar.bio.nyu.edu) (Krek et al., 2005). All these computational programs 
allow the investigator to enter a specific ‘‘Gene Symbol’’ and the algorithm will 
compute all predicted miRNA target sites within that gene. Additionally, these 
algorithms will determine all the putative mRNA targets of a given miRNA. 
To further reduce the number of putative miRNAs that may repress the expression of a 
given mRNA target is necessary further in silico analysis since many miRNA targets 
predicted by seed sequence matching often fail validation tests in vivo (Diadian and 
Hobert, 2006). Contextual features may also govern miRNA/mRNA interactions. For 
example, a large portion of a given mRNA sequence is highly structured and only 
certain single-stranded regions may be accessible for binding with miRNAs. Thus, 
complex RNA secondary structures may prevent miRNA/ mRNA interactions; in fact, a 
common feature of most validated targets is that miRNAs preferentially target 3’-UTR 
sites that do not have complex secondary structures and are located in accessible regions 
of the RNA based on favourable thermodynamics (Zhao Y et al., 2007). Since RNA 
accessibility may be a critical feature of miRNA target recognition and the free energy 
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Figure 8 |  Proposed flow diagram microRNA validation 
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(ΔG) of the 70 nucleotides flanking the 50 and 30 sides of the predicted miRNA binding 
sites is determined using mFold program (http://mfold.bioinfo.rpi.edu/).  
All target genes were analyzed by TargetScan (release 4.2) because it evaluates various 
features of microRNA/mRNA interactions, and targets are ranked by ‘total context 
score’, which is based on site type, site number and site context.  
The list of predicted up-regulated targets gene and pathways of the hypothetical targets 
of miR-519d are showed on line (http://www.targetscan.org/cgi-
bin/vert_42/targetscan.cgi?mirg=hsa-miR-519d). 
 
4. Identification interesting pathway 
The lists of gene target with a favourable context score (<-0.30) were combined and 
organized by KEGG GENES Database (http://www.genome.jp/kegg/). KEGG is a 
collection of gene catalogs for all complete genomes and some partial genomes 
generated from publicly available resources, mostly NCBI Ref Seq. It integrates current 
knowledge on molecular interaction networks such as pathways and complexes, 
information about genes and proteins generated by genome projects and information 
about biochemical compounds and reactions. The role of adipose tissue as a dominant 
regulator of whole-body lipid and glucose homeostasis is now well established, based 
on extensive experimental evidence, which shows that dysfunctions in adipose tissue 
metabolism have a direct impact on lipid and glucose homeostasis. Many observations 
reinforce the concept that normal lipid and glucose homeostasis as well as normal 
insulin sensitivity requires fully functional adipose tissue. Adipose dysfunctions in 
obesity include secretions of abnormal levels of cytokines linked to insulin resistance, 
impairments in triglyceride storage and increases in lipolysis (Guilherme et al., 2008). 
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From these foundations, interestingly, were tried, among those identified two very 
interesting pathways, own those indicated over which are often involved in obesity and 
obesity-associated diseases: insulin and adipocytokine signaling pathways. 
The following genes were selected from these two pathways: 
    PPARA = target of miR-519d with 5 binding sites  
                              (1:7mer, which is highly conserved, and 3:7mer and 1:7mer-1A,   
                               which are poorly conserved) 
 SLC2A4 = target of miR-519d with only 1 binding site  
                              (7mer-m8 highly conserved) 
All these genes have a good microRNA accessibility (ΔG analysis) evaluated with the 
mFold program (http://mfold.bioinfo.rpi.edu/) and a favourable context score. 
From bioinformatics predictions may predict a large number of putative miRNA 
binding sites on a specific targets, but a rapid and reproducible assay is needed to 
quickly evaluated interaction sites are functional. 
 
5. RT-PCR and Western-Blot 
The mRNA expression of these putative target genes in SAT from obese and non-obese 
subjects was verified by RT-PCR (Fig. 9). The levels of SCL2A4 did not differ between 
obese and non obese subjects whereas the levels of PPARA were particularly high in 
OBM (mean RQ±SD: 6.5±3.0) versus respectively CM and CW. The effects of up-
regulation of microRNA-519d are obvious by Western-Blotting. We chose 2 OBW and 
2 OBM who had different levels of microRNA-519d to determine a dose-dependent 
effect on target protein. Protein concentrations of SLC2A4, is similar in the obese and 
non obese subjects, whereas the levels of PPARA protein are different and the data 
suggests that PPARA plays a relevant role in the development of obesity (Fig 10). 
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Figure 9 | Gene expression analysis of selected genes in subcutaneous adipose tissue from morbidly 
obese subjects.  
Predicted targets of up-regulated miR-519d in obese subjects are SCL2A4 and PPARA were analyzed by 
RT-PCR. 
A: obese women [OBW], CW, control women pool; B: obese men [OBM, CM, control men pool.  
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Figure 10 | PPARA is down-regulated in subcutaneous adipose tissue from morbidly obese subjects.  
Western-blot analyses of selected predicted targets SCL2A4 and PPARA of up-regulated miR-519d in 
obese subjects.  
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6. Luciferase assay 
A common experimental reporter system able to verify predicted miR/mRNA pairings, 
is luciferase reporter assays.  
The rationale for using this assay is that the binding of a given miRNA to its specific 
mRNA target site will repress reporter protein production thereby reducing 
activity/expression that can be measured and compared to a control. 
The experimental approach is to clone the 3’-UTR of the target gene of interest , or 
(repeated) fragments thereof, immediately downstream of the luciferase measuring the 
expression of the construct in transfected cells.  
3’-UTR of PPARA is composed of about 8 Kb of nucleotides and presents five miR-
519d binding sites, one conserved and four poorly conserved.  
The plasmids used were pGL3-control encoding for firefly luciferase, a control 
luciferase reporter plasmid, and were co-transfected with pRL-PPARA, coding for 
Renilla luciferase under CMV promoter, including two miR-519d binding sites (one 
conserved and one poorly conserved) on five contained in a part of the 3’ UTR region 
of the PPARA gene. The direction of the inserted 3’ UTR region was confirmed by 
PCR and sequencing after ligation.  
 
7. Validation of the interaction between miR-519d and the 
PPAR-alpha 3’UTR 
Its possible to tests effects of the miR-519d transfecting the chemically synthesized miR 
into cells together with the reporter plasmid harboring multiple, concatenated binding 
sites designed to mimic the mismatched base pairing typical of known endogenous 
miR/mRNA pairings.  
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Previously, 2’-O-methyl oligonucleotides have been demonstrated to mediate inhibition 
of miRNAs in vitro (Meister et al., 2004) and in vivo (Leaman et al., 2005) and has 
found wide use as miRNA inhibitors. Recently, LNA-modified oligonucleotides can 
mediate this inhibition of miRNAs equally efficient way. LNA has features and results 
in very high hybridization affinity towards complementary single stranded RNA 
without compromising specificity and show improved antisense efficacy and higher Tm 
toward complementary RNA compared to 2’-O-methyl oligonucleotides of the same 
sequence (Ørom et al., 2006). 
From these premises, LNA-modified oligonucleotides anti-miRNA and pre-miRNA 
were used  to verify that miRNA activity with luciferase assay. 
Successively, we transfected another cell line, HEK 293, that have an higher efficient of 
transfection than precedent cell line (Chub-S7) (Fig. 11). 
A related approach, with certain advantages as outlined later, is to synthesize target 
mRNAs by in vitro transcription and transfect cells directly with an mRNA/miR mix.  
After transfection into HEK-293 cells of the pRL-PPARA plasmid with pre-mir-519d, 
who mimics the function of the same microRNA, in increasing concentrations (100nM, 
200nM e 300nM). We observed an inhibition of luciferase activity of about 50% 
compared to pRL-PPARA plasmid transfection alone (Fig. 11a). Addition of premiR-
519d was able to promote the repression of luciferase activity in a concentration-
dependent manner.    
In a second experiment, after transfection into HEK-293 cells of the pRL-PPARA 
plasmid with only one concentration of pre-mir-519d (200nM), we inhibited 
endogenous pre-mir activity using antisense oligonucleotides, antimir-519d, 
complementary to the same microRNA, in increasing concentrations (100nM and 
200nM).  
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We observed a block of the repression of luciferase activity compared to pRL-PPARA 
plasmid transfection with the premir-519d (200nM)  (Fig. 11b). 
This data demonstrates that there is an effective, specific and functional interaction 
between miR-519d and the 3’UTR of the PPARA mRNA suggesting that changes in 
miR-519d levels may effectively modulate the expression of genes regulated by this 
transcription factor. 
Application of this method makes the further assumption that miRNA-mediated 
repression results from a graded reduction in translation of all functional mRNA 
molecules, rather than a complete translational shutdown of a subpopulation thereof.  
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Figure 11 | MiR-519d binds and functionally interacts with PPARA 3’UTR. 
(A) pre-miR-519d dose-depending inhibited the expression of a Renilla luciferase-expressing construct 
that contains the 3’ UTR region of the PPARA gene containing miR-519d putative binding sites;  
(B) anti-miR- 519d dose-dependently blocked the pre-miR-519d-induced inhibition of the expression of 
Renilla luciferase containing the PPARA 3’UTR region. Each sample, except the positive control, was 
transfected with a 200 nM final concentration of pre-miR-519d and the indicated concentration of the 
anti-miR-519d. *P<0.05; **P<0.01. 
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Discussion
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A growing body of evidence suggests that microRNAs are important regulators of cell 
growth (Ambros, 2004), differentiation (Hwang et al., 2006), and apoptosis (Wienholds 
et al., 2005). In support of the significance of miRNAs in normal development and 
physiology, recent mouse miRNA ‘‘knockout’’ studies demonstrated that depending 
upon which miRNA gene was deleted, mice were left immuno-deficient (Thai et al., 
2007) or with heart defects (Zhao el al., 2007). Implications drawn from these studies 
support the hypothesis that dysregulation of miRNA function may lead to human 
disease. As disease-specific miRNAs are identified, the validation of novel targets 
within a disease pathway of interest may lead to novel therapeutic strategies.  
Therefore, it is critically important to be able to identify and validate miRNA/ 
mRNA target pairs. Although not perfect, computational algorithms and ΔG analyses 
allow for the identification of putative miRNA/mRNA targets. Once identified, the 
authenticity of a functional miRNA/mRNA target pair can be validated by fulfilling 
criteria. First, miRNA/mRNA target interaction must be verified. Second, the predicted 
miRNA and mRNA target gene must be co-expressed. Third, a given miRNA must have 
a predictable effect on target protein expression. That is, if gene is a true target of a 
given miRNA, its miRNA mimic will decrease the target gene expression level while a 
miRNA inhibitor will increase the target gene expression level. Fourth and final, 
miRNA-mediated regulation of target gene expression should equate to altered 
biological function. 
There is currently no consensus model for the mode by which miR affect the process of 
mRNA translation. Few studies have, so far, addressed this possibility. Detailed 
biochemical characterization of the miR mechanism will depend on the development 
and application of tractable cell-free translation systems that preserve the key 
physiological features of their action. Further, it may be just as instructive to determine 
‘‘where’’ in the cell miR-dependent translational repression takes place, as to 
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investigate ‘‘how’’ it happens. An important task will also be to attempt independent 
verification of key findings that led the different investigators to propose their divergent 
models (Clancy et al., 2007). 
This work reports for the first time an high-throughput screening by microarray 
analysis on microRNA expression profiling on human subcutaneous adipose tissue from 
obese and lean subjects to improve our understanding of global transcriptional 
regulation in severe obesity. A global analysis of miRNA expression pattern identified  
five miRNAs involved in obesity. From this study the miR-519d was significantly 
higher the in obese subjects than in the non obese pools. PPARA was predicted to be a 
miR-519d target by five binding-sites on the PPARA 3’ UTR. Interactions on each sites 
act independently and aren’t cooperative (Grimson et al., 2007). We found PPARA 
protein levels down-regulated in obese subjects than in the non obese pools. It may be 
that miR-519d acts through different molecular mechanisms but we were able to 
validate experimentally the interplay between miR-519d and PPARA in a context-
dependent manner.  
PPARA was the first PPAR to be identified and is highly expressed in tissues that 
rely on fatty acid oxidation as their primary energy substrate, namely, heart, liver and 
skeletal muscle (Braissant et al., 1996).  
Nuclear receptors, especially peroxisome proliferator-activated receptor-alpha (PPAR 
alpha)  is a ligand-activated transcription factors that regulate the metabolism of glucose 
and genes encoding fatty acid oxidation enzymes. PPAR-alpha is necessary for the 
induction of peroxisomal biogenesis in response to peroxisome proliferators. Most 
known PPAR-alpha target genes encode enzymes involved in cellular fatty acid 
oxidation including the peroxisomal, mitochondrial, and cytochrome p450 pathways. 
PPAR-alpha is activated by fatty acids or inhibitors of mitochondrial long-chain fatty 
acid import. These data, taken togheter suggest that PPAR-alpha serves as a cellular 
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'lipostat', transducing changes in cellular lipid levels to the transcriptional regulation of 
target genes involved in fatty acid utilization.  
To test the hypothesis that PPAR-alpha is activated as a component of the cellular 
lipid homeostatic response, Djouadi et al. (1998) characterized the expression of PPAR-
alpha target genes in response to a perturbation in cellular lipid oxidative flux caused by 
pharmacologic inhibition of mitochondrial fatty acid import. Inhibition of fatty acid 
oxidative flux caused a feedback induction of PPAR-alpha target genes encoding fatty 
acid oxidation enzymes in liver and heart. In mice lacking PPARA (Ppara -/-), 
inhibition of cellular fatty acid flux caused massive hepatic and cardiac lipid 
accumulation, hypoglycemia, and death in 100% of male, but only 25% of female Ppara 
-/- mice. The metabolic phenotype of male Ppara -/- mice was rescued by a 2-week 
pretreatment with beta estradiol. These results demonstrated a pivotal role for PPAR-
alpha in lipid and glucose homeostasis in vivo and implicated estrogen signaling 
pathways in the regulation of cardiac and hepatic lipid metabolism.  
Studies in rodents demonstrated the involvement of PPAR-alpha nuclear receptor 
in lipid homeostasis, with a sexually dimorphic control of circulating lipids, fat storage, 
and obesity (Costet et al., 1998).  
Adenovirus-induced hyperleptinemia causes rapid disappearance of body fat in 
normal rats, presumably by upregulating fatty acid oxidation within white adipocytes. 
To determine the role of PPARA expression, which was increased during the rapid loss 
of fat, Lee et al. (2002) infused adenovirus-leptin into Ppara-null and Ppara-wildtype 
mice. Despite similar degrees of hyperleptinemia and reduction in food intake, 
epididymal fat pad weight declined 55% in wildtype but only 6% in null mice; liver 
triacylglycerol fell 39% in the wildtype group but was unchanged in the null group. 
Carnitine palmitoyltransferase-1 rose 52% in the wildtype mice but did not increase in 
the null mice. The most striking transcription difference was the 3-fold rise in PGC1-
 
 
 51 
alpha (PPARGC1) in white adipose tissue that occurred in Ppara-wildtype but not in 
Ppara-null mice. Moreover, baseline expression of PGC1-alpha in the null mice was 
below normal. The role of the PGC1 coactivator in mitochondrial biogenesis, 
thermogenesis, and gluconeogenesis is well established. Lee et al. (2002) found the 
most plausible interpretation of the findings in white adipose tissue to be that leptin 
induces, through upregulation of PGC1-alpha expression, a PPARA-dependent increase 
in mitochondrial biogenesis that increases fatty acid oxidation sufficiently to deplete 
triglyceride stores with a relatively modest increase in the transcription and/or activities 
of the enzymes of fatty acid oxidation. Hypertension and diabetes are common side 
effects of glucocorticoid treatment. Human hepatocytes treated with dexamethasone and 
a PPAR-alpha agonist showed induction of PPARA and gluconeogenic gene expression. 
Kintscher et al. have shown the increased expression of PPARA (measured as mRNA 
level) in overweight (BMI 29±3 kg/m2) as compared with normal weight patients. They 
suggested that characteristic for obesity and metabolic syndrome elevation of FA in 
blood leads to permanent PPARA stimulation, since free fatty acids are ligands for these 
transcription factors and itself activates its expression. PPARA activation may lead to 
the stimulation of beta-oxidation and this process turns into lipotoxicity, and 
cardiomyopathy parallel with development of obesity (Kintscher et al., 2003).  
The present work has led to the identification of an “interactome” network 
involved in the pathogenesis of obesity. We have shown that integration of microRNA-
protein expression and clinical data can be used to generate a network of potential 
functional associations with obesity and alterations in gene expression are able to 
perturb this relationship. This is in line with our results indicating that in human obesity 
miR-519d-mediated repression of the PPARA. Taken together, the data obtained in 
animal models show that PPARA plays a relevant role in lipid storage in adipose tissue 
and increases adiposity. The results will help to improve the understanding of the 
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pathogenesis of multifactorial diseases such as obesity and provide possible novel 
therapeutic targets. 
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